Publication

A liver secretome gene signature-based approach for determining circulating biomarkers of NAFLD severity

PLoS One 7(10):e0275901, 2022

Hagemann CA, Legart C, Møllerhøj MB, Madsen MR, Hansen HH, Kønig MJ, Helgstrand F, Hjørne FP, Toxværd A, Langhoff JL, Kielgast UL, Gluud LL, Ægidius H, Rigbolt KTG, Vilsbøll T, Jelsing J, Knop FK

Subjects

Human Bioinformatics Non-alcoholic steatohepatitis/Metabolic dysfunction-associated steatohepatitis (NASH/MASH)Image analysis Immunohistochemistry Liver biopsy Next-generation sequencing RNA sequencing

Share this page

Resource Library

Related resources

Poster

Metabolic, biochemical, histological, and transcriptomic effects of semaglutide in the GAN diet-induced and biopsy-confirmed ob/ob mouse model of NASH

Poster

Prophylactic and therapeutic hepatoprotective effects of semaglutide in the CDAA-HFD mouse model of advanced NASH with progressive fibrosis

Publication

Glucagon resistance at the level of amino acid turnover in obese subjects with hepatic steatosis

Poster

A liver secretome gene signature-based approach for determining circulating biomarkers of NAFLD severity

Subjects

Related resources

For further information

Contact us

Gubra